Frequency and voltage partitioning in presence of renewable energy resources for power system (example: North Chile power network)

This paper investigates techniques for frequency and voltage partitioning of power network based on the graph-theory. These methods divide the power system into distinguished regions to avoid the spread of disturbances and to minimize the interaction between these regions for frequency and voltage control of power system. In case of required active and reactive power for improving the performance of the power system, control can be performed regionally instead of a centralized controller. In this paper, renewable energy sources are connected to the power network to verify the effect of these sources on the power systems partitioning and performance. The number of regions is found based on the frequency sensitivity for frequency partitioning and bus voltage for voltage partitioning to disturbances being applied to loads in each region. The methodology is applied to the north part of Chile power network. The results show the performance and ability of graph frequency and voltage partitioning algorithm to divide large scale power systems to smaller regions for applying decentralized controllers.Peer ReviewedPostprint (published version

Mitigation of voltage imbalance in power distribution system using MPC-controlled packed-U-cells converter

Delivering high power quality in single-phase distribution has witnessed more challenges especially with the increased penetration of single-phase distributed generation (DG). This paper proposes a smart solid-state-based transformer, which aims to replace traditional ones, for single-phase distribution laterals, and provide load balancing and protection to the three-phase main feeders, that is based on connecting the single-phase lateral to the three-phase main feeder through a power electronics converter. This converter transfers balanced power from and to the three-phase feeder while automatically regulating the lateral single-phase voltage, hence, assuring high power quality without requiring any transformer on-load tap changer. A 7-level packed-U-cells (PUC) single-phase inverter topology was used to deliver single-phase regulated sinusoidal voltage to the AC loads, and at the same time, it is able to deliver DC power to DC loads. The simulation and hardware-in-the-loop (HIL) results have shown that the proposed topology delivers high power quality for both AC and DC loads under different operating scenarios. Moreover, the converter can play the role of a solid-state protection device coordinated with other up- and downstream protective devices. Finally, this system can be integrated within the smart grid allowing more flexibility for automation and efficient control of the grid. - 2019 The Authors. Energy Science & Engineering published by the Society of Chemical Industry and John Wiley & Sons Ltd.This work was made possible by Qatar University Internal Grant no. QUCP?CENG?EE?15/16?4

Influence of High Volume RHA on Properties of Cement Mortar

This work study the impact of partial cement replacement by high volume Rice Husk Ash (RHA) on some characteristics of cement mortar like compressive strength and flexural strength at different ages. In this research, RHA was used in three different ratios (20, 40, and 60)% as a cement substitution and the findings were compared with control mixture (0% RHA). The findings demonstrated that the replacement of cement by RHA reduced the compressive strength of all selected ratios and the increase in the content of RHA lead to reduce compressive strength comparative to control sample with 100% cement as a binder at all ages. However, the flexural strength results indicated that the RHA in 20% showed approximately same results as control sample at early ages while increasing the curing period lead to improve flexural strength. Increasing RHA higher than 20% lead to decrease Flexural strength at all selected ages

Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19

Importance: Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are receiving TNF inhibitors remains insufficiently understood. Objective: To examine the association between the receipt of TNF inhibitor monotherapy and the risk of COVID-19-associated hospitalization or death compared with other commonly prescribed immunomodulatory treatment regimens among adult patients with IMIDs. Design, Setting, and Participants: This cohort study was a pooled analysis of data from 3 international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and confirmed or suspected COVID-19 using online data entry portals. Adults (age ≥18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included. Exposures: Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy. Main Outcomes and Measures: The main outcome was COVID-19-associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations. Results: A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age was 48.8 (16.5) years. The most common IMID diagnoses were rheumatoid arthritis (2146 patients [35.3%]) and Crohn disease (1537 patients [25.3%]). A total of 1297 patients (21.3%) were hospitalized, and 189 patients (3.1%) died. In the pooled analysis, compared with patients who received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among those who received a TNF inhibitor in combination with azathioprine/6-mercaptopurine therapy (odds ratio [OR], 1.74; 95% CI, 1.17-2.58; P =.006), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61; P =.001), methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56; P <.001), and Jak inhibitor monotherapy (OR, 1.82; 95% CI, 1.21-2.73; P =.004) but not among those who received a TNF inhibitor in combination with methotrexate therapy (OR, 1.18; 95% CI, 0.85-1.63; P =.33). Similar findings were obtained in analyses that accounted for potential reporting bias and sensitivity analyses that excluded patients with a COVID-19 diagnosis based on symptoms alone. Conclusions and Relevance: In this cohort study, TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with IMIDs

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.

OBJECTIVE: To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). METHODS: We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders. RESULTS: Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity. CONCLUSIONS: People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people

Changes in perception of treatment efficacy are associated to the magnitude of the nocebo effect and to personality traits

The nocebo effect in motor performance consists in a reduction of force and increase of fatigue following the application of an inert treatment that the recipient believes to be effective. This effect is variable across individuals and it is usually stronger if conditioning -exposure to the active effect of the treatment- precedes a test session, in which the treatment is inert. In the current explorative study we used a conditioning procedure to investigate whether subjective perception of treatment effectiveness changes between the conditioning and the test session and whether this change is related to dispositional traits and to the nocebo-induced reduction of force. Results showed that 56.1% of participants perceived the treatment as more effective in the test than in the conditioning session, had a more pronounced reduction of force, felt more effort and sense of weakness and were characterized by lower levels of optimism and higher anxiety traits compared to the other 43.9% of participants, who conversely perceived the treatment as less effective in the test session than in the conditioning. These findings highlight for the first time a link between changes in perception of treatment effectiveness, personality traits and the magnitude of the nocebo response in motor performance

Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19

Importance: Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are receiving TNF inhibitors remains insufficiently understood. Objective: To examine the association between the receipt of TNF inhibitor monotherapy and the risk of COVID-19-associated hospitalization or death compared with other commonly prescribed immunomodulatory treatment regimens among adult patients with IMIDs. Design, Setting, and Participants: This cohort study was a pooled analysis of data from 3 international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and confirmed or suspected COVID-19 using online data entry portals. Adults (age ≥18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included. Exposures: Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy. Main Outcomes and Measures: The main outcome was COVID-19-associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations. Results: A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age was 48.8 (16.5) years. The most common IMID diagnoses were rheumatoid arthritis (2146 patients [35.3%]) and Crohn disease (1537 patients [25.3%]). A total of 1297 patients (21.3%) were hospitalized, and 189 patients (3.1%) died. In the pooled analysis, compared with patients who received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among those who received a TNF inhibitor in combination with azathioprine/6-mercaptopurine therapy (odds ratio [OR], 1.74; 95% CI, 1.17-2.58; P =.006), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61; P =.001), methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56; P <.001), and Jak inhibitor monotherapy (OR, 1.82; 95% CI, 1.21-2.73; P =.004) but not among those who received a TNF inhibitor in combination with methotrexate therapy (OR, 1.18; 95% CI, 0.85-1.63; P =.33). Similar findings were obtained in analyses that accounted for potential reporting bias and sensitivity analyses that excluded patients with a COVID-19 diagnosis based on symptoms alone. Conclusions and Relevance: In this cohort study, TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with IMIDs

CMV reduction in a three-to-seven phase direct matrix converter using SVPWM

The pulse-width modulation (PWM)-controlled modern electric drives causes some serious problems such as the generation of common-mode voltage (CMV) and high dv/dt. The CMV might cause high-frequency leakage currents that flow through the possible path that is bearing of the motor. Thus, the flow of current through the motor bearing leads to its premature failure. One of the main challenges in developing PWM methods for control of motor drives is the problem of CMV and its reduction/elimination. In this study, a modulation technique based on space-vector approach is developed to reduce the CMV in a three-to-seven-phase direct matrix converter. CMV reduction becomes possible by selecting suitable zero-voltage vectors for a specific duration and the use of a selected set of active vectors for the output voltage synthesis. The proposed space-vector PWM (SVPWM) for the reduction of CMV is performed with a seven-phase R-L load to show the viability of the proposed technique. The proposed SVPWM technique is implemented experimentally in dSPACE working in conjunction with field-programmable gate array processor board using a system generator. Hardware results that validate the proposed control algorithm are discussed. - The Institution of Engineering and Technology 2019This publication was made possible by the Qatar University internal Grant QUCP-CENG-17\18-2. The statements made herein are solely the responsibility of the authors.Scopu

Common mode voltage reduction technique in a three-to-three phase indirect matrix converter

In this study, common mode voltage (CMV) reduction using space vector pulse-width modulation (SVPWM) technique is proposed for a three-phase induction motor drive fed by a three-to-three phase indirect matrix converter (MC). The proposed SVPWM effectively reduces the peak of the CMV without affecting the output voltage gain. By adopting the proposed SVPWM there is no change in the dv/dt of CMV at the terminal of the machine when compared to the existing method. The proposed control is possible by proper placement of zero vectors in the rectifier stage and discarding zero voltage vectors in the inverter stage of the indirect MC. The control technique is implemented in MATLAB/Simulink environment. Hardware setup is developed and control algorithm is implemented using dSPACE working in conjunction with the FPGA interface board. The results of the proposed SVPWM are compared with the existing method of CMV elimination and the improvement is established. The simulation results obtained are verified with the experimental results. The obtained results confirm a reduction of CMV by 48% (peak) and validate the viability of the proposed scheme in a three-phase induction motor drive system. The Institution of Engineering and Technology.Scopu